More than 30 million people in 46 countries joined together to participate in Myeloma Action Month (MAM), a campaign in March to raise awareness…
News
Carvykti (ciltacabtagene autoleucel; cilta-cel) has been recommended for approval in Europe by the Committee for Medicinal Products for Human Use (CHMP), an arm of the…
Black people with multiple myeloma live longer than white patients with similar disease symptoms when both receive the same new and updated medical treatments,…
Even if they’re fully vaccinated, multiple myeloma patients still have an increased risk of COVID-19 infection compared with people without cancer, according to a…
Patient registries are a hot topic of rare disease research and many organizations are taking advantage of this resource by signing up their patient communities…
The therapy Sarclisa (isatuximab) extended survival by nearly seven months in relapsed/refractory multiple myeloma patients also given Pomalyst (pomalidomide) and dexamethasone as standard…
Horizon Therapeutics has launched its #RAREis Representation program aimed at increasing diversity, equity, and inclusion among patients with rare diseases. There are about 400 million…
The U.S. Food and Drug Administration (FDA) has given fast track designation to Harpoon Therapeutics’ HPN217 as a potential immunotherapy for people with relapsed, refractory …
Bionews, the publisher of this website, hosted a virtual panel discussion on Rare Disease Day 2022, taking a deeper dive into what it’s like…
The U.S. Food and Drug Administration (FDA) has approved the CAR T-cell therapy Carvykti (ciltacabtagene autoleucel) — formerly known as cilta-cel — for certain…
